Please assess the completion status of the following clinical trial:

Trial Title: Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal at least 5 years; Screening bone mineral density more than or equal to 2.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.~Exclusion Criteria:~Metabolic bone disease other than osteoporosis; Taking approved medications for osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- lasofoxifene 0.5 mg/day (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None
- lasofoxifene 0.25 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).